beta blockers and glp 1 glp-1 Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, Regulation of GLP-1 and Glucagon

Jensen JM, Scherer A, Wanke C, Brutigam M, Bongiovanni S, Letzkus M, Staedtler F, Kehren J, Zuehlsdorf M, Schwarz T, et al

Storage: Store in cool, dark, and dry places

Some peptide therapies are FDA-approved for certain conditions

Peptides are usually detectable for minutes to hours, depending on the type, dose, and metabolism

Always follow the specific instructions given by your healthcare provider

This is, however, rather speculative and requires future investigation that should involve a direct measurement of the dopamine release after intra-VTA or intra-NAc GLP-1 application during a food reward task in vivo